Cargando…
PAK1-blockers: Potential Therapeutics against COVID-19()
PAK1 (RAC/CDC42-activated kinase 1) is the major “pathogenic” kinase whose abnormal activation causes a wide variety of diseases/disorders including cancers, inflammation, malaria and pandemic viral infection including influenza, HIV and COVID-19. Since Louis Pasteur who developed a vaccine against...
Autores principales: | Maruta, Hiroshi, He, Hong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier B.V.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7166201/ https://www.ncbi.nlm.nih.gov/pubmed/32313880 http://dx.doi.org/10.1016/j.medidd.2020.100039 |
Ejemplares similares
-
Chemical evolution for taming the ‘pathogenic kinase’ PAK1
por: Maruta, Hiroshi, et al.
Publicado: (2020) -
PAK1 and PAK4 as therapeutic targets for Ewing sarcoma: a commentary
por: Parks, Sydney E., et al.
Publicado: (2021) -
Therapeutic potential of Pak1 inhibition for pain associated with
cutaneous burn injury
por: Guo, Yiqun, et al.
Publicado: (2018) -
PAK1, PAK1Δ15, and PAK2: similarities, differences and mutual interactions
por: Grebeňová, Dana, et al.
Publicado: (2019) -
Functional Deficits in Pak5, Pak6 and Pak5/Pak6 Knockout Mice
por: Furnari, Melody A., et al.
Publicado: (2013)